Key Insights on Gross Profit: Takeda Pharmaceutical Company Limited vs MiMedx Group, Inc.

Takeda vs. MiMedx: A Decade of Gross Profit Trends

__timestampMiMedx Group, Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 20141055580001256834000000
Thursday, January 1, 20151670940001271973000000
Friday, January 1, 20162126080001173296000000
Sunday, January 1, 20172859200001274610000000
Monday, January 1, 20183227250001437534000000
Tuesday, January 1, 20192561740002201424000000
Wednesday, January 1, 20202089040002203504000000
Friday, January 1, 20212153320002462160000000
Saturday, January 1, 20222195250002783406000000
Sunday, January 1, 20232668430002832257000000
Monday, January 1, 20242832257000000
Loading chart...

Unleashing the power of data

A Tale of Two Companies: Gross Profit Trends from 2014 to 2023

In the competitive landscape of pharmaceuticals, Takeda Pharmaceutical Company Limited and MiMedx Group, Inc. present a fascinating study in contrasts. Over the past decade, Takeda has consistently demonstrated robust growth, with its gross profit soaring by approximately 125% from 2014 to 2023. This Japanese giant's financial prowess is evident, peaking at an impressive $2.83 trillion in 2023.

Conversely, MiMedx Group, Inc., a smaller player in the industry, has shown a more modest trajectory. Despite a 153% increase in gross profit from 2014 to 2023, its figures remain a fraction of Takeda's, highlighting the disparity in scale and market reach. Notably, MiMedx's data for 2024 is missing, leaving room for speculation on its future performance.

These insights underscore the dynamic nature of the pharmaceutical sector, where strategic positioning and market size play pivotal roles in financial outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025